Chronic Myeloid Leukemia: Optimizing Use of TKIs to Individualize Treatment Across the Disease Spectrum

Get the latest evidence on optimizing the use of TKI-based therapies for patients with chronic myeloid leukemia, including strategies to personalize and sequence treatment to prevent disease progression or overcome resistance, reduce toxicities, and incorporate patient preferences in this text module with accompanying downloadable slides.

Share

Program Content

Activities

Chronic Myeloid Leukemia Treatment
Chronic Myeloid Leukemia: Optimizing Use of TKIs to Individualize Treatment Across the Disease Spectrum
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 15, 2024

Expires: February 14, 2025

Activities

Chronic Myeloid Leukemia Treatment Slides
Chronic Myeloid Leukemia: Optimizing Use of TKIs to Individualize Treatment Across the Disease Spectrum
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: August 12, 2024

Expires: August 11, 2025

Faculty

cover img faculity

Fadi Haddad, MD

Assistant Professor
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.

Bristol Myers Squibb

Novartis Pharmaceuticals Corporation